Market Place
Sourcing Support
LIB Therapeutic Submits BLA for Lerodalcibep to Treat Elevated LDL
16 Dec 2024 //
BUSINESSWIRE
LIB`s Lerodalcibep Positive Phase 3 Data At EAS Congress
29 May 2024 //
BUSINESSWIRE
Lib Lerodalcibep Eas Abstracts: 92nd Congress Presentations Accepted
23 May 2024 //
BUSINESSWIRE
LIB Therapeutics Announces Positive Results from LIBerate-HR Study: A 52-Week
08 Apr 2024 //
BUSINESSWIRE
LIB To Participate in Piper Sandler Virtual Cardio Day from ACC 2024 Conference
03 Apr 2024 //
BUSINESSWIRE
LIB Announces Abstracts Accepted for Presentation at the American College
01 Apr 2024 //
BUSINESSWIRE
LIB & Partner Hasten Announce Lerodalcibep Clinical Trial
19 Mar 2024 //
BUSINESSWIRE
LIB Therapeutics Announces Abstracts Accepted for Presentation
13 Feb 2024 //
BUSINESSWIRE
LIB Therapeutics Announces Appointment of Ingrid Choong as CBO
07 Dec 2023 //
BUSINESSWIRE
LIB Announces Completion of the Global Phase 3 LIBerate Program of Lerodalcibep
14 Nov 2023 //
BUSINESSWIRE
LIB Therapeutics and Hasten Company Announce $325 Million Collaboration
12 Sep 2023 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.